246 related articles for article (PubMed ID: 38338802)
21. Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms.
Vladareanu AM; Popov V; Bumbea H; Onisai M; Ilea A; Dobrea C; Miulescu M
J Med Life; 2011; 4(1):97-101. PubMed ID: 21505581
[TBL] [Abstract][Full Text] [Related]
22. Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm.
Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
[TBL] [Abstract][Full Text] [Related]
23. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
24. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
De Stefano V; Teofili L; Leone G; Michiels JJ
Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199
[TBL] [Abstract][Full Text] [Related]
25. Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.
Rai P; Kumar P; Mishra S; Aggarwal R
Indian J Gastroenterol; 2016 Sep; 35(5):366-371. PubMed ID: 27633031
[TBL] [Abstract][Full Text] [Related]
26. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
27. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
28. JAK2 mutations across a spectrum of venous thrombosis cases.
Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
[TBL] [Abstract][Full Text] [Related]
29. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
[TBL] [Abstract][Full Text] [Related]
30. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
31. [JAK2 mutation and thrombosis - recommendations for screening].
Linnemann B; Lindhoff-Last E
Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
[No Abstract] [Full Text] [Related]
32. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.
Kiladjian JJ; Cervantes F; Leebeek FW; Marzac C; Cassinat B; Chevret S; Cazals-Hatem D; Plessier A; Garcia-Pagan JC; Darwish Murad S; Raffa S; Janssen HL; Gardin C; Cereja S; Tonetti C; Giraudier S; Condat B; Casadevall N; Fenaux P; Valla DC
Blood; 2008 May; 111(10):4922-9. PubMed ID: 18250227
[TBL] [Abstract][Full Text] [Related]
33. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.
Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C;
J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676
[TBL] [Abstract][Full Text] [Related]
34. Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms.
Akpan IJ; Stein BL
Curr Hematol Malig Rep; 2018 Jun; 13(3):183-190. PubMed ID: 29644531
[TBL] [Abstract][Full Text] [Related]
35. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
Colaizzo D; Amitrano L; Tiscia GL; Iannaccone L; Gallone A; Grandone E; Guardascione MA; Margaglione M
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):459-62. PubMed ID: 18600100
[TBL] [Abstract][Full Text] [Related]
36. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
de Suray N; Pranger D; Brenard R
Acta Gastroenterol Belg; 2008; 71(1):39-41. PubMed ID: 18396750
[TBL] [Abstract][Full Text] [Related]
37. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.
Brière JB
Semin Thromb Hemost; 2006 Apr; 32(3):208-18. PubMed ID: 16673275
[TBL] [Abstract][Full Text] [Related]
38. A novel subtype of myeloproliferative disorder? JAK2V617F-associated hypereosinophilia with hepatic venous thrombosis.
Dasari S; Naha K; Hande M; Vivek G
BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23997080
[TBL] [Abstract][Full Text] [Related]
39. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
40. Abdominal thromboses of splanchnic, renal and ovarian veins.
De Stefano V; Martinelli I
Best Pract Res Clin Haematol; 2012 Sep; 25(3):253-64. PubMed ID: 22959542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
